Literature DB >> 24908401

Cetuximab in refractory squamous cell carcinoma of the anal canal.

Jane E Rogers1, Cathy Eng.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24908401     DOI： 10.1007/s12029-014-9626-7

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  12 in total

1.  Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case.

Authors:  Lan K Phan; Paulo M Hoff
Journal:  Dis Colon Rectum       Date:  2007-03       Impact factor: 4.585

2.  Epidermal growth factor receptor expression in anal canal carcinoma.

Authors:  Lyly H Lê; Runjan Chetty; Malcolm J Moore
Journal:  Am J Clin Pathol       Date:  2005-07       Impact factor: 2.493

3.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

4.  Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status.

Authors:  Nadine Lukan; Philipp Ströbel; Andreas Willer; Melanie Kripp; Dietmar Dinter; Sabine Mai; Andreas Hochhaus; Ralf-Dieter Hofheinz
Journal:  Oncology       Date:  2009-11-17       Impact factor: 2.935

5.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Authors:  Robert Pirker; Jose R Pereira; Aleksandra Szczesna; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Ihor Vynnychenko; Keunchil Park; Chih-Teng Yu; Valentyn Ganul; Jae-Kyung Roh; Emilio Bajetta; Kenneth O'Byrne; Filippo de Marinis; Wilfried Eberhardt; Thomas Goddemeier; Michael Emig; Ulrich Gatzemeier
Journal:  Lancet       Date:  2009-05-02       Impact factor: 79.321

6.  The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series.

Authors:  Muhammad W Saif; Ewa Kontny; Kostas N Syrigos; Armin Shahrokni
Journal:  J Oncol       Date:  2011-06-13       Impact factor: 4.375

7.  Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer.

Authors:  Hanna Barmettler; Paul Komminoth; Mathias Schmid; Donat Duerr
Journal:  Case Rep Oncol       Date:  2012-08-09

8.  KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC).

Authors:  Andrea Casadei Gardini; Laura Capelli; Paola Ulivi; Massimo Giannini; Eva Freier; Stefano Tamberi; Emanuela Scarpi; Alassandro Passardi; Wainer Zoli; Angela Ragazzini; Dino Amadori; Giovanni Luca Frassineti
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

9.  Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy.

Authors:  Ninoska N Silva; Cathy Eng
Journal:  J Adv Pract Oncol       Date:  2012-05

10.  Management of two cases of recurrent anal carcinoma.

Authors:  Eiko Klimant; Maurie Markman
Journal:  Case Rep Oncol       Date:  2013-09-12
View more
  4 in total

Review 1.  Pharmacotherapy of Anal Cancer.

Authors:  Jane E Rogers; Cathy Eng
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

2.  Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal.

Authors:  Jane E Rogers; Ninoska N Silva; Cathy Eng
Journal:  J Gastrointest Oncol       Date:  2015-10

Review 3.  Systemic Therapies for Advanced Squamous Cell Anal Cancer.

Authors:  Francesco Sclafani; Sheela Rao
Journal:  Curr Oncol Rep       Date:  2018-05-04       Impact factor: 5.075

4.  Stage IV anal canal squamous cell carcinoma with long-term survival: a case report.

Authors:  Katsuji Sawai; Takanori Goi; Noriyuki Tagai; Hidetaka Kurebayashi; Mitsuhiro Morikawa; Kenji Koneri; Masato Tamaki; Makoto Murakami; Yasuo Hirono; Hiroyuki Maeda
Journal:  Surg Case Rep       Date:  2022-06-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.